MUTATED TRUNCATED mt-pfkA GENE FOR THE SYNTHESIS OF ACTIVE SHORTER FRAGMENT OF 6-PHOSPHOFRUCTO-1-KINASE

The invention deals with mutated truncated mX-pfkA gene encoding shorter fragment of 6-phosphofructo-1-kinase (PFK1), with no need for phosphorylation of the protein molecule for activation, that is not significantly inhibited by citric acid and/or its salts and ATP molecules. Active 49-52 kDa fragm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	TEVZ GREGOR, LEGISA MATIC, CAPUDER MAJA, MLAKAR TINA, BENCINA MOJCA, OVEN DARIJA
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PEPTIDES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS SUGARS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention deals with mutated truncated mX-pfkA gene encoding shorter fragment of 6-phosphofructo-1-kinase (PFK1), with no need for phosphorylation of the protein molecule for activation, that is not significantly inhibited by citric acid and/or its salts and ATP molecules. Active 49-52 kDa fragment encoded by mt-pfltk gene, retains positive regulatory properties of the native protein and is activated in the presence of specific activators, while citric acid and ATP, important metabolites that function as feed back inhibitors in higher organisms do not reduce its activity. The invention deals with the use of modified shorter fragment in biotechnological processes for fabricating primary and secondary metabolites.